## Planning for Action: The Impact of an Asthma Action Plan Decision Support Tool Integrated into an Electronic Health Record (EHR) at a Large Health Care System

Lindsay Kuhn, MHS, PA-C, Kelly Reeves, BSN, RN, Yhenneko Taylor, PhD, Hazel Tapp, PhD, Andrew McWilliams, MD, MPH, Andrew Gunter, MD, Jeffrey Cleveland, MD, and Michael Dulin, MD, PhD

Introduction: Asthma is a chronic airway disease that can be difficult to manage, resulting in poor outcomes and high costs. Asthma action plans assist patients with self-management, but provider compliance with this recommendation is limited in part because of guideline complexity. This project aimed to embed an electronic asthma action plan decision support tool (eAAP) into the medical record to streamline evidence-based guidelines for providers at the point of care, create individualized patient handouts, and evaluate effects on disease outcomes.

Methods: eAAP development occurred in 4 phases: web-based prototype creation, multidisciplinary team engagement, pilot, and system-wide dissemination. Medical record and hospital billing data compared frequencies of asthma exacerbations before and after eAAP receipt with matched controls.

*Results:* Between December 2012 and September 2014, 5174 patients with asthma ( $\sim$ 10%) received eAAPs. Results showed an association between eAAP receipt and significant reductions in pediatric asthma exacerbations, including 33% lower odds of requiring oral steroids (P < .001), compared with controls. Equivalent adult measures were not statistically significant.

Conclusions: This study supports existing evidence that patient self-management plays an important role in reducing asthma exacerbations. We show the feasibility of leveraging technology to provide guideline-based decision support through an eAAP, addressing known challenges of implementation into routine practice. (J Am Board Fam Med 2015;28:382-393.)

Keywords: Asthma, Clinical Decision Support Systems, Electronic Health Records, Outcomes Assessment

Asthma is a chronic airway disease that can be difficult to manage, resulting in poor outcomes and

high costs. According to 2012 data from the Centers for Disease Control and Prevention, the prevalence of asthma is increasing and is estimated to affect 8.3% of the US population.<sup>1</sup> More than 25.5 million people are affected, of whom over 6.8 million are children.<sup>2</sup> Unfortunately, many patients with asthma lack adequate control of their symptoms, which negatively affects their overall quality of life and leads to increased use of expensive acute care services. The burden of asthma is exceedingly high. Each year, 2 million emergency department (ED) visits, 439,000 hospitalizations, and 3,000 deaths are a result of poorly controlled asthma.<sup>3</sup>

This article was externally peer reviewed. Submitted 29 August 2014; revised 13 February 2015; accepted 23 February 2015.

From the Department of Family Medicine (LK, KR, HT, AM, MD), Dickson Advanced Analytics (YT, MD), and Department of Pediatrics (AG, JC), Carolinas HealthCare System, Charlotte, NC.

Funding: This study was funded by Carolinas HealthCare System and the Agency for Healthcare Research and Quality (grant no. R18 HS19946–01).

Conflict of interest: US patent application for "Methods and Systems for an Electronic Asthma Action Plan," application no. 61/877,491 (LEK, KR, MD); provisional patent filed September 13, 2013, and nonprovisional patent conversion filed September 14, 2014.

Corresponding author: Lindsay E. Kuhn, MHS, PA-C, Carolinas HealthCare System, Department of Family Medicine,

<sup>2001</sup> Vail Avenue, Suite 400, Mercy Medical Plaza, Charlotte, NC 28207 (E-mail: lindsay.kuhn@carolinashealthcare.org).

An asthma action plan (AAP) is a tool designed to assist patients with self-management of their chronic disease. In fact, guidelines from the National Heart, Lung, and Blood Institute (NHLBI) recommend that all patients with asthma be provided with a plan that includes instructions for daily management and how to recognize and handle worsening symptoms.<sup>4</sup> AAPs are particularly helpful for patients with moderate or severe persistent asthma, a history of severe exacerbations, or poorly controlled asthma.<sup>4</sup> While the content of each AAP may vary to some extent,5-7 typical plans outline which medications and what actions to take in the following 3 zones: (1) the "green zone," which includes medications taken every day to achieve and maintain good control; (2) the "yellow zone," which includes which rescue medications to add when asthma gets worse and when to see their provider for follow-up; and (3) the "red zone," which details what medications to take and how to seek care in the event of an asthma emergency. Previous studies demonstrate that patients receiving an AAP as part of their self-management education have higher satisfaction with their care, increased medication adherence, and fewer acute care visits compared with patients with no AAP.8-11 A Cochrane review of 36 studies showed significant reductions in both ED visits (relative risk, 0.82; 95% confidence interval [CI], 0.73-0.94) and hospitalizations (relative risk, 0.64; 95% CI, 0.50-0.82) among patients with an AAP as part of optimal self-management compared with usual care.<sup>10</sup>

Although provision of an AAP to every patient with asthma is considered to be the standard of care, provider compliance with this recommendation has been limited.<sup>12-17</sup> Barriers to provider compliance include lack of time, inexperience, and insufficient confidence in generating appropriate recommendations, as well as perceptions that patients may be nonadherent to AAPs or unable to self-manage.<sup>18,19</sup> Providers also underutilize other recommendations in the NHLBI's guidelines, including assessments of asthma severity and control and the stepwise approach to managing asthma when choosing medication options for their patients.<sup>15,20</sup> Adherence to the asthma guidelines is poor in part because of their complexity. The most recent version of the NHLBI's asthma guidelines is 440 pages long and requires providers to recall variations in the recommendations that are dependent on patient age, severity or level of control, and therapy step to tailor medication selection.<sup>4</sup>

The complexities and intricacies of asthma management require innovative approaches to improve quality gaps and patient outcomes. Technology can be leveraged to link and filter the guidelines to providers at the point of care, resulting in increased adherence and reduced exacerbations. By incorporating technology into providers' asthma workflow, these solutions may increase the likelihood of patients receiving guideline-based recommendations and an AAP, thus facilitating their active involvement in their own care.

The goal of this project was to develop an electronic AAP decision support tool (eAAP) within the electronic health record (EHR) that could streamline the evidence-based NHLBI guidelines for providers, while also creating an individualized instructional handout for patients to use as their selfmanagement plan. An additional aim was to prospectively evaluate the effectiveness of the eAAP's integration across the outpatient network of this large health care system. We hypothesized that patients with asthma receiving an eAAP would have fewer exacerbations after 3, 6, and 12 months compared with patients not receiving an eAAP.

### Methods

### Setting

Carolinas HealthCare System is one of the largest comprehensive networks in the United States. The fully integrated system comprises over 40 hospitals and over 900 care locations, connecting delivery of care throughout North Carolina, South Carolina, and Georgia. The health care system's 3000 physicians and advanced care practitioners, along with 15,000 nurses, participated in over 11 million encounters in 2013.<sup>21</sup> One million patients are actively managed through the primary care network, including approximately 50,000 patients with asthma. Despite advances in care delivery, the health care system had an average of 6378 ED visits and 1384 hospitalizations with a primary diagnosis of asthma each year from 2012 to 2014.

### eAAP Development

The eAAP was developed in 4 phases (Figure 1). Phase 1 involved the creation of a web-based eAAP prototype by researchers from the health care system's Department of Family Medicine (https://

## Figure 1. Electronic asthma action plan decision support tool (eAAP) development phases. EHR, electronic health record.



asthma.carolinashealthcare.org). This prototype facilitated the ability to make design revisions quickly and easily.

To embed this tool into the EHR, a multidisciplinary team was engaged in phase 2. Key personnel were identified by the project's lead physician with support from system administration. Physicians, advanced care practitioners, and nurses with a special interest in asthma care were invited to participate. In addition, information technology specialists, administrators, and quality specialists from across the health care system partnered with the researchers to refine the eAAP and incorporate it into the EHR (Table 1). Because the involvement of key personnel was critically important to the project's success, the team was reassessed regularly to ensure appropriate representation.

Beginning in February 2012, the team met regularly every 4 to 6 weeks, either in person or via teleconference. Design enhancements during implementation involved rapid cycles of change using provider feedback to make modifications. Point of care convenience and ease of provider workflow was of utmost importance when modifying the tool. Each resulting output was reviewed and tested again to ensure proper functioning and positive feedback from end users. Examples of changes that went through these rapid cycle improvements for the subsequent patient handout included (1) modifications to the "green zone" verbiage for when no daily controller medication is needed; (2) specifications for ED visit and hospital follow-up after discharge; (3) the addition of routes (inhaled or by mouth) to the medication descriptions; and (4) reformatting to print in color when applicable.

Once ready for production, the eAAP entered phase 3, where it was piloted at 5 outpatient primary care practices from December 2012 through July 2013. During this pilot stage, the development team continued to enhance the eAAP based on feedback from end users. Informed by lessons learned in the pilot, the team created a job aid and a web-based training video to assist with adoption of the tool.

Finally, in August 2013, the eAAP entered phase 4: dissemination with widespread implementation at over 100 primary care practices across the health care system. This dissemination made the eAAP available for ambulatory providers to use for any patient with asthma who, based on their clinical judgment, would benefit from its receipt. When specially requested, an eAAP team member would present on-site training sessions at individual practices to promote uptake of the tool.

The final eAAP product meets the general criteria of typical AAPs in that it instructs patients in how to manage their asthma on a daily basis and what to do in times of worsening symptoms or exacerbations. In addition, the eAAP provides (1) instantaneous determination of peak flow thresholds calculated using an algorithm based on patient demographic information, (2) guided assessment of asthma severity or control, (3) the ability to auto-

Team Members (n)	Credentials/Type (n)	Role Descriptions
Physician leader (1)	MD, PhD (1)	Oversaw the development and implementation of the eAAP; principal investigator of research project that partially funded the work
Project manager (2)	MBA, PT (1) MHS, PA-C (1)	Coordinated team to meet goals and keep the project on track
Content experts (2)	MHS, PA-C (1) BSN, RN (1)	Incorporated the 2007 NHLBI asthma guidelines into the eAAP's recommended stepwise treatment options
Clinical advisors (8)	MD (6) RRT (1) MSN, RN (1)	Provided feedback regarding usability, functionality, and accessibility with regard to patient care and work flow
Programmers (5)	RN (1) BA/BS (5)	Built the platform of the program into the EHR
Information services (5)	BBA, RRT (1) BSN, RN (3) BS (1)	Handled technical challenges blending clinical and application areas
Quality specialists (5)	MHS, PA-C (1) BSN, RN (2) MHA, CPHQ (1) BS, RRT (1)	Ensured the integration of appropriate care measures into the tool; team of nurses supported its use in the field
Administrators (2)	MSN, RN (1) BSN, RN (1)	Supported system-wide expansion
Evaluation support (3)	PhD (2) MSPH (1)	Provided research and data analysis for outcomes measures
Pilot sites (5)	Pediatrics (2) Family medicine (2) Teen specialty (1)	Provided initial feedback during the experimental phase before the system-wide launch

Table 1.	Ambulator	y Asthma Action	n Plan	Committee	Team	Members	and Role	Descrip	otions

eAAP, electronic asthma action plan decision support tool; EHR, electronic health record; NHLBI, National Heart, Lung, and Blood Institute.

matically populate EHR fields that satisfy asthma appropriate care expectations, (4) guideline-based decision support for medication selection, (5) electronic prescribing, and (6) generation of an individualized AAP patient handout to support selfmanagement (Figures 2 and 3).

#### Data Collection and Analysis

Data for evaluation of this project were obtained from the EHR system and hospital billing data. Patients with an eAAP were identified by querying the EHR each month. For each patient with a completed eAAP, a unique patient identifier and

# Figure 2. Screenshot of the electronic asthma action plan decision support tool (eAAP) in the electronic health record.

ative Problem Ltd	Step 1:	Step 2:	Step 1:	Step 4:	Step 5:	Step 6:
penta and Problem Inega Semenary VI Ingenist Il Nationa Case Semenary III Manistranova III Manistranova III Manistranova	SABA PPN	Low-Dose ICS     LTRA	Low-Dose ICS +     LTRA     Mediam-Dose ICS	Medium Dose ICS + LABA     Medium-Dose ICS + LTRA     Medium-Dose ICS + LABA + LTRA	<ul> <li>Hub-Dose ICS + LABA</li> <li>Hub-Dose ICS + LTRA</li> <li>Hub-Dose ICS + LABA</li> <li>+LTRA</li> </ul>	High-Dose ICS + LAB     Coal Steroid     High-Dose ICS + LTR     Coal Steroid     High-Dose ICS + LAB     +LTRA + Oral Steroid
n & Internet and and Internet Internet In Chart Inter & Proceedants	Cover Cover Pulmic a day C Pulmic C Floves	se Inhaled Corticosteroid beclomethasone) 40 mcg sp ort Flexhaler (budesonide) ort Resputes (budesonide) 0 fl HFA (finticasone) 44 mcg	<ul> <li>Leukotriene Receptor / ray - 1 puff inhaled twice a 90 mcg actuation - 1 puff in 0.25/2 mL - 1 neb inhaled or spray - 1 puff inhaled twice</li> </ul>	Antagonist (Preferred) day + Singulair (montelaka haled twice a day + Singula ice a day + Singulair (mont a day + Singulair (montels	ist) 5 mg - 1 by month once i iir (montelukast) 5 mg - 1 by elukast) 5 mg - 1 by month o ikast) 5 mg - 1 by month onc	a day y mouth once once a day ce a day
in & Demonstrations forth fortune dr. Chart for & Proceedings man Alasses content & Schedult	Low-Do Quar ( Pulmic a day Pulmic Flores Medium	se Inhaled Corticosteroid beclomethasone) 40 mcg sp ort Fleshaler (budesonide) fort Respules (budesonide) 0 it HFA (fluticasone) 44 mcg -Dose Inhaled Corticoster	<ul> <li>Leukotriene Receptor / ray - 1 puff inhaled twice a 90 mcg actuation - 1 puff in 0.25-2 mL - 1 neb inhaled or xpray - 1 puff inhaled twice</li> <li>coid (Preferred)</li> </ul>	Antagonist (Preferred) day + Singulair (monteluka haled twice a day + Singul ice a day + Singulair (montelu a day + Singulair (montelu	ist) 5 mg – 1 by mouth once i iir (montelukast) 5 mg - 1 by clukast) 5 mg - 1 by mouth o ikast) 5 mg - 1 by mouth onc	a day 9 mouth once 90cce a day 9c a day

This screenshot shows the step-wise approach to medication selection of "Green Zone" daily controller options that are age and dose specific. the date the eAAP was performed were captured. The following binary (yes/no) events were identified as outcomes: ED visits for asthma, asthmarelated hospitalizations, and use of oral steroids for asthma exacerbations in the outpatient setting (prescription orders for prednisone, prednisolone, methylprednisolone, or dexamethasone). Asthmarelated ED visits and hospitalizations were identified from hospital billing data and included events with an International Classification of Diseases, Ninth Revision, code of 493 as the primary diagnosis. The combined measure of "any exacerbation," a binary variable indicating whether a patient had any of the 3 individual outcome measures, also was assessed.

We compared outcomes for eAAP recipients with those of nonrecipients to determine whether changes in outcomes were significantly different.

We used propensity score matching to select appropriate controls. Propensity score matching is a method to balance differences between treatment and control groups by modeling the probability of being selected to the treatment group and matching intervention participants with controls based on that probability. For this analysis, we used an established propensity matching macro based on the nearest neighbor algorithm.<sup>22</sup> Controls were selected from a pool of 25,926 patients who attended a health care system practice where no providers had used the eAAP tool. Patients were matched based on age, race/ethnicity, gender insurance category, and the number of ED visits, hospitalizations, and oral steroid prescription orders for asthma in the previous 12 months. In addition, the month of the first eAAP was matched to the visit month for the control group to ensure visits within the same time

Figure 3. Screenshot of the electronic asthma action plan decision support tool (eAAP) patient handout for self-management.

Inted: 08/15/14 1044 AS	thma Action Plan	Page: 1 of 1			
Practice:	Office #:	Fax #:			
<ul> <li>You / your child should have regularly schedu hospital within 3-5 days</li> </ul>	uled asthma check-ups and be seen after any visit to the ER or				
<ul> <li>No Smoking in the home or car (even if you</li> <li>Annual flu vaccine is recommended for every</li> <li>Remove or control your / your child's triggers</li> </ul>	r child is not with you) one over 6 months of age who has asthma : Smoke, Indoor pets, Pollen, Respiratory infection mittee	ons or flu, Dust, dust			
	Illes Ocertaelles Medicine Free	Part			
(Your asthma is well controlled )	Use Spacer with all appropriate inhalers	ry Day			
You should have: - No wheezing - No coughing - No chest lightness	Take these controller medications: Qvar (beciomethasone) 80 mcg/spray - 1 puff inh Zyrtec (cetirizine) 5 mL by mouth at bedtime	aled twice a day			
<ul> <li>No waking up at night because of asthma</li> <li>No problems with play because of asthma</li> <li>Peak flow is more than 138</li> </ul>	15 minutes before exercise use Yellow Zone med	ficine (below)			
YELLOW ZONE - Take Action (Your asthma is getting worse)	on Take Quick Relief Medicine (Continue Green Zone daily medicine and add rer Use Spacer with all appropriate inhalers				
fou may have: Wheezing Coughing Chest tightness First signs of a cold Coughing at right Bask for a life may Bit to 198	Take these rescue medications: Albuterol 2.5 mg/3mL nebulized - 1 neb inhaled e OR Albuterol 90 mcg/puff inhaled HFA - 2 puffs inhale needed	very 4-6 hours as needed ad every 4-6 hours as			
	Call your healthcare provider for an appointment Yellow Zone symptoms continue for 24 hours or rescue medicine more than 2 times a week.	or further instructions if you / your child requires			
RED ZONE - Get Help Now (This is an Emergency )	Take Quick Relief Medicine (Continue Green Zone daily medicine an Use Spacer with all appropriate inhalers	d add rescue medicine)			
You may have: - Quick relief medicine is not helping - Wheezing is worse - Faster breathing - Blue lips or nailbeds	Take these rescue medications: Albuterol 90 mog/puff inhaled HFA - 4 puffs inhal 3 times OR Albuterol 2.5 mg/3mL nebulized - 1 neb inhaled e	ed every 20 minutes up to avery 20 minutes up to 3			
Chest and neck pulled in with each breath     Peak flow is less than 86	Do Not Wait! Call Your Provid	ler Now!			
	If they cannot be reached Call 911 OR go direct	y to the Emergency Room			
Signatures if needed for school:					
Provider Signature:	Date: .	Time:			
School Health Nurse Signature:	Date: .	Time:			
Carolinas HealthCare System		ALLERGY			



period. Propensity scores were calculated using logistic regression. The match rate for children was 65.3% (2783/4259) and the match rate for adults was 97.5% (892/915). The odds of primary outcomes for the eAAP recipient group versus the controls were computed using generalized estimating equations to adjust for correlation between matched samples.

The analysis also compared differences between the percentage of pediatric and adult patients with an outcome in the period before their first eAAP to the percentage of patients with an outcome in the period after the eAAP using the McNemar test statistic. Each outcome was evaluated 3, 6, and 12 months before and after the date of each patient's first eAAP. Because participants had varying follow-up times, analyses were grouped by duration of follow-up. All analyses were conducted using SAS version 9.4 (SAS, Inc., Cary, NC).

#### Results

#### Usage

From December 2012 through September 2014, 6484 eAAPs were completed across the health care system's outpatient network (Figure 4). Demographics of the 5174 unique patients with asthma who received an eAAP showed that the vast majority (82%) were children (Table 2). Overall, patients were diverse with regard to gender, race/ethnicity, and insurance status (Table 2). The total number of eAAP recipients represents approximately 10% of the health care system's asthma population.

Peaks in usage occurred before the beginning of the school year during the cold and influenza sea-

Table 2. Demographic Characteristics for the Sample
of Patients Receiving the Electronic Asthma Action Plan
Decision Support Tool ( $N = 5174$ )

	Children (0–17 Years) (n = 4259; 82%)	Adults (≥18 Years) (n = 915; 18%)
Mean age (years)	9.3	40.0
Gender (%)		
Female	37.7	69.6
Male	62.3	30.4
Race/ethnicity (%)		
African American	34.0	42.3
Caucasian	34.0	41.4
Hispanic/Latino	8.4	3.9
Asian	1.3	0.2
Native American	0.1	0.3
Multiracial	1.5	0.1
Other race	3.4	1.9
Missing	17.3	9.9
Insurance (%)		
Commercial	56.0	53.4
Medicare	N/A	15.5
Medicaid	41.1	22.2
Self-pay/charity	0.0	0.3
Other/unknown	2.9	8.5

N/A, not applicable.

	Chi	dren	Ad	ults
	eAAP (n = 2783)	$\begin{array}{c} Control\\ (n = 2783) \end{array}$	eAAP (n = 892)	$\begin{array}{c} Control\\ (n = 892) \end{array}$
Mean age, years (SD)	9.3 (4.3)	9.3 (4.6)	40.1 (17.1)	40.2 (16.6)
Race/ethnicity, n (%)				
African American	1,044 (37.5)	1,063 (38.2)	377 (42.3)	373 (41.8)
American Indian or Alaska Native	15 (0.5)	11 (0.4)	8 (0.9)	8 (0.9)
Asian	35 (1.3)	33 (1.2)	2 (0.2)	0
Caucasian	1,220 (43.8)	1,219 (43.8)	377 (42.3)	404 (45.3)
Hispanic	20 (0.7)	21 (0.8)	2 (0.2)	1 (0.1)
Other	187 (6.7)	184 (6.6)	39 (4.4)	36 (4.0)
Unknown	262 (9.4)	252 (9.1)	87 (9.8)	70 (7.8)
Insurance category, n (%)				
Charity	2 (0.1)	1 (0)	2 (0.2)	2 (0.2)
Commercial	1,452 (52.2)	1,432 (51.5)	488 (54.7)	513 (57.5)
Medicare				
Medicaid	1,247 (44.8)	1,260 (45.3)	202 (22.6)	180 (20.2)
Other	38 (1.4)	41 (1.5)	8 (0.9)	10 (1.1)
Self-pay	1 (0.1)		1 (0.1)	1 (0.1)
Unknown	44 (1.6)	49 (1.8)	49 (5.5)	48 (5.4)
Gender, n (%)				
Female	1,091 (39.2)	1,111 (39.9)	620 (69.5)	622 (69.7)
Male	1,692 (60.8)	1,672 (60.1)	272 (30.5)	270 (30.3)
ED visit in prior 12 months, n (%)	132 (4.7)	127 (4.6)	40 (4.5)	41 (4.6)
Hospitalization in prior 12 months, n (%)	40 (1.4)	45 (1.6)	4 (0.4)	3 (0.3)
Outpatient oral steroid in prior 12 months, n (%)	716 (25.7)	803 (28.9)	181 (20.3)	159 (17.8)
Follow-up time, n (%)				
3 months	184 (20.6)	226 (25.3)	373 (13.4)	494 (17.8)
6 months	392 (43.9)	374 (41.9)	931 (33.5)	780 (28.0)
12 months	316 (35.4)	292 (32.7)	1,479 (53.1)	1,509 (54.2)

## Table 3. Data Frequencies in the Matched Sample of Patients Receiving the Electronic Asthma Action Plan Decision Support Tool

eAAP, electronic asthma action plan decision support tool; ED, emergency department; SD, standard deviation.

son in the autumn and the allergy season in the spring. Utilization also seemed to increase in 6-month intervals, consistent with the health care system's appropriate care expectation, which generates a reminder in the EHR to complete an AAP every 6 months for patients with asthma. By October 2013, 30 to 40 practices were using the eAAP each month, with new sites continually adopting the tool (Figure 4).

#### Outcomes

Tables 3 and 4 show the distribution of characteristics and outcomes for matched samples of children and adults. Compared with the controls, eAAP recipients did not differ significantly in the odds of ED visits or hospitalizations for asthma at 3, 6, or 12 months (Table 5). Children receiving an eAAP, however, had 33% lower odds of receiving an oral steroid for asthma (12-month odds ratio [OR], 0.67; 95% CI, 0.56–0.81). The combined exacerbation outcome was also significant (12month OR, 0.73; 95% CI, 0.61–0.87). Equivalent measures for adults were not statistically significant.

In addition, the results showed an association between receipt of an eAAP and a significant reduction in pediatric asthma exacerbations at 3, 6, and 12 months using pre/post analyses (Table 6). Asthma-related ED visits declined by 41% at 3 months (P < .05), 32% at 6 months (P < .05), and 40% at 12 months (P < .001) after children received an eAAP. Children also received fewer oral steroids, a marker of exacerbation, after receiving an eAAP; use decreased by 51% at 3 months (P <

Outcomes by Follow up	Ch	ildren	Adults		
Time	eAAP (n = 2783)	Control (n = $2783$ )	eAAP (n = 892)	Control ( $n = 892$ )	
ED visit, n (%)					
3 months after	31 (1.1)	26 (0.9)	14 (1.6)	10 (1.1)	
6 months after	56 (2.0)	53 (1.9)	20 (2.2)	18 (2.0)	
12 months after	89 (3.2)	84 (3.0)	29 (3.3)	23 (2.6)	
Hospitalization, n (%)					
3 months after	6 (0.2)	11 (0.4)	2 (0.2)	1 (0.1)	
6 months after	12 (0.4)	15 (0.5)	3 (0.3)	4 (0.4)	
12 months after	16 (0.6)	18 (0.6)	6 (0.7)	4 (0.4)	
Outpatient oral steroid, n (%)					
3 months after	162 (5.8)	223 (8.0)	62 (7.0)	76 (8.5)	
6 months after	237 (8.5)	297 (10.7)	88 (9.9)	93 (10.4)	
12 months after	219 (7.9)	311 (11.2)	60 (6.7)	60 (6.7)	
Any exacerbation, n (%)					
3 months after	194 (7.0)	250 (9.0)	76 (8.5)	84 (9.4)	
6 months after	282 (10.1)	329 (11.8)	105 (11.8)	107 (12.0)	
12 months after	261 (9.4)	344 (12.4)	76 (8.5)	70 (7.8)*	

 Table 4. Acute Asthma Outcome Frequencies in the Matched Sample of Patients Receiving the Electronic Asthma

 Action Plan Decision Support Tool

\*Counts for outcomes 3, 6, and 12 months after the intervention include only patients with enough follow-up to capture those outcomes. eAAP, electronic asthma action plan decision support tool; ED, emergency department.

.001), 41% at 6 months (P < .001), and 34% at 12 months (P < .001). Pediatric inpatient hospital stays for asthma demonstrated a similar decreasing trend; however, significance was not reached be-

cause of the low incidence of hospitalizations. Among children with at least 12 months of follow-up (n = 1925), overall asthma exacerbation rates dropped by 34% (P < .001) (Table 6).

Asthma Action Plan Decision Support Tool Versus Controls							
	Children	Adults					
Outcomes by Follow-up Time	Odds Ratio (95% CI)	P Value	Odds Ratio (95% CI)	P Value			
ED visit							
3 months after	1.19 (0.17-2.00)	.501	1.41 (0.62-3.20)	.416			
6 months after	1.03 (0.69–1.55)	.869	1.14 (0.57-2.30)	.709			
12 months after	1.00 (0.67–1.49)	.998	1.53 (0.79-2.94)	.207			
Hospitalization							
3 months after	0.54 (0.20–1.48)	.232	2.00 (0.18-22.16)	.571			
6 months after	1.05 (0.43-2.60)	.908	0.23 (0.03-2.11)	.195			
12 months after	1.17 (0.42-3.23)	.765	0.61 (0.10-3.71)	.594			
Outpatient oral steroid							
3 months after	0.71 (0.58–0.87)	.001	0.80 (0.57–1.13)	.209			
6 months after	0.73 (0.61–0.88)	<.001	0.88 (0.64–1.20)	.402			
12 months after	0.67 (0.56-0.81)	<.001	0.91 (0.62–1.35)	.652			
Any exacerbation							
3 months after	0.76 (0.63-0.92)	.005	0.90 (0.65-1.24)	.502			
6 months after	0.79 (0.67–0.94)	.006	0.91 (0.68–1.22)	.592			
12 months after	0.73 (0.61–0.87)	<.001	1.02 (0.71–1.45)	.923			

 Table 5. Odds Ratios Comparing the Odds of Acute Asthma Outcome Events Among Recipients of the Electronic

 Asthma Action Plan Decision Support Tool Versus Controls

CI, confidence interval; ED, emergency department.

-							
Outcomes	Follow-up Time						
	3 Months before	3 Months after	6 Months before	6 Months after	12 Months before	12 Months after	
Children, n (%)	3 Months (1	n = 4,259)	6 Months (i	n = 3,358)	12 Months (	(n = 1,925)	
ED visit	72 (1.7)	44 (1.0)*	85 (2.5)	57 (1.7)*	93 (4.8)	55 (2.9) <sup>†</sup>	
Hospitalization	16 (0.4)	8 (0.2) <sup>‡</sup>	21 (0.6)	12 (0.4)	18 (0.9)	$9 (0.5)^{\ddagger}$	
Outpatient oral steroid	467 (11.0)	232 (5.4) <sup>†</sup>	510 (15.2)	303 (9.0) <sup>†</sup>	413 (21.5)	273 (14.2) <sup>†</sup>	
Any exacerbation	537 (12.6)	277 (6.5) <sup>†</sup>	585 (17.4)	357 (10.6) <sup>†</sup>	484 (25.1)	319 (16.6) <sup>†</sup>	

6 Months (n = 717)

17 (2.4)

1(0.1)

89 (12.4)

106 (14.8)

19 (2.7)

1(0.1)

98 (13.7)

112 (15.6)

 Table 6. Acute Asthma Outcomes Among Patients Receiving the Electronic Asthma Action Plan Decision Support

 Tool by Time Since First Use of the Tool

Change from prior period determined using the McNemar test:, \*P< .05, †P < .001, †P < .10. ED, emergency department.

15 (1.6)

2(0.2)

63 (6.9)<sup>†</sup>

78 (8.5)\*

3 Months (n = 915)

17 (1.9)

1(0.1)

106 (11.6)

117 (12.8)

Equivalent pre/post measures for adults were not statistically significant at 6 or 12 months, likely because of the smaller sample size; however, a 41% decrease in outpatient oral steroids (P < .001) and a 34% reduction in any exacerbation (P < .05) occurred 3 months after receiving an eAAP (Table 6).

Post hoc power analyses revealed < 40% power to detect the observed differences in ED visits and hospitalizations in our matched pediatric sample. The matched adult sample provided 69% power to detect differences in inpatient stays but < 40%power for all other outcomes.

#### Discussion

Adults, n (%)

ED visit

Hospitalization

Any exacerbation

Outpatient oral steroid

Significant reductions in asthma exacerbationrelated outcomes, namely, oral steroid prescription orders, were seen in association with receipt of an eAAP among children, but not adults, in the outpatient setting of a large health care system. The majority of plans (82%) were created for children. This higher portion of pediatric recipients was an expected finding because it is customary for schools to request or require a copy of the AAP for their records, where it is used as an order for medication administration during exacerbations.

This eAAP not only satisfies the traditional elements of basic AAPs but also leverages technology to improve the efficiency of care delivery and adherence to evidence-based guidelines with decision support capabilities to improve asthma control. Furthermore, because this eAAP is embedded in the EHR, workflow is optimized for busy providers, and continuity of care is achieved across the health care system.

12 Months (n = 316)

19 (6.0)

2 (0.6) 60 (19.0)

76 (24.1)

19 (6.0)

3 (1.0)

56 (17.7)

70 (22.2)

Little in the current literature describes the development, integration, and evaluation of an eAAP. Roberts et al<sup>23</sup> developed an electronic pictorial AAP and incorporated it into a separate software package but not the EHR. Hanson et al<sup>24</sup> studied the electronic sharing of AAPs between providers and schools through a secure portal but did not evaluate disease-specific outcomes. This novel evaluation of asthma outcomes associated with use of an EHR-embedded decision support tool adds to knowledge of the effectiveness of these tools to improve disease outcomes.

The integration of clinical decision support within the EHR is becoming increasingly popular as a result of meaningful use legislation, and future medical practice is anticipated to progressively tie financial incentives to clinical outcomes.<sup>25</sup> Studies show improvements in preventive care services, appropriate care, clinical outcomes, and cost when providers have access to current medical knowledge and evidence-based guidance at the point of care.<sup>25–28</sup> Other examples of EHR-based clinical decision support include interventions around diabetes<sup>29</sup> and bipolar disorder with depression.<sup>30</sup>

If the use of an eAAP results in better asthma control and fewer asthma exacerbations, as these results suggest, the impact on the cost of care could be significant. Direct health care costs for patients with asthma vary considerably depending on their

level of asthma control. In a study of Kaiser Permanente's Southern California System, there was a \$3499 difference in direct costs for those with uncontrolled versus controlled asthma: \$6797 versus \$3298, respectively.<sup>31</sup> A national study by Ivanova et al<sup>32</sup> found a difference of \$4212, and Barnett and Nurmagambetov<sup>33</sup> found a difference of \$3259 using the 2004 Medical Expenditure Panel Survey.<sup>34</sup> Extrapolating from these numbers, it can be assumed that asthma control saves approximately \$4000 per patient. Thus, on a regional level, Carolinas HealthCare System, which cares for over 50,000 patients with asthma, could potentially see large savings associated with improved outcomes. Much broader financial savings implications are possible for payors and the larger US health care system.

A limitation of this study is that the observational design yielded association, not causality, between receipt of an eAAP and improved disease outcomes for children with asthma. Comparisons with matched control showed significantly lower odds of children requiring oral steroids for acute exacerbations 3, 6, and 12 months after receipt of an eAAP, but no change in ED visit or hospitalization rates was demonstrated because there was insufficient power to detect small differences. A randomized controlled trial, which was not performed because of a lack of resources, would strengthen the evaluation.

Nevertheless, the downward trends in acute care visits persisted across the 3 different observation periods in pre/post analyses. Since 2010, asthma has been a disease of interest at this health care system, with various asthma initiatives being explored simultaneously. A related limitation is the challenge of differentiating the impact of the eAAP on asthma exacerbations while other concurrent asthma management projects were underway. Concurrent projects included deployment of an integrated approach to asthma care in which a team of quality nurses focused on guiding practices in the use of EHR asthma appropriate care and an asthma shared decision making intervention located at 6 underserved practices.<sup>35,36</sup>

To promote high-quality care for patients with asthma in the ambulatory setting, the health care system monitors several appropriate care expectations. These expectations, seen as alerts in a "health maintenance module," are easily viewable on the opening summary page in the EHR of a patient with asthma. Some alerts are measured and reported back to providers with regard to their quality goals, which may be tied to compensation, whereas others, including biannual AAP completion satisfied by the eAAP, are currently not measured. Having no incentive for completion of this expectation may partly explain the relative underuse of the eAAP in comparison to the health care system's overall asthma population.

Pediatric providers may be more aware of the optional AAP expectation because asthma is at this time the only disease state monitored for children at the health care system. For this reason, extra attention may be paid to the completion of both the measured and unmeasured expectations, including the eAAP for children. Adult patients, on the other hand, may have numerous alerts in their health maintenance modules, depending on their comorbid conditions, prompting providers to prioritize completion of the measured expectations and thus explaining the relative underutilization of the eAAP in adults.

Management of asthma in adults not only is challenging because of complicating comorbidities but also is contingent on various behavioral factors. Minimizing exposure to known triggers, avoiding smoking tobacco products, and adhering to the prescribed regimen, namely, inhaled corticosteroids, are paramount to achieving successful control.<sup>37</sup> Poor adherence often is associated with difficulties with inhaler devices, complicated regimens, side effects, and cost.<sup>38</sup> These difficulties, in addition to the small sample size, may explain why adults achieved less impact of receiving an eAAP.

Finally, there may be instances in which patients are incorrectly diagnosed or coded with asthma, leading them to have asthma appropriate care expectations erroneously included in their health maintenance modules. Perhaps some children had wheezing associated with a respiratory illness, or some adults have chronic obstructive pulmonary disease as opposed to asthma. Providers may choose not to perform an eAAP in these cases, introducing selection bias. As currently designed, whether to complete an eAAP for an individual patient is at the providers' discretion, based on their clinical assessment.

Currently, the eAAP is used only in the ambulatory setting. Further expansion of the eAAP into the ED and hospital environments is planned to

create one unified approach to asthma care that is linked across all care settings within the health care system. It is anticipated that this expansion will help to achieve quality measures in the acute care locations. Since 2007, the Joint Commission has mandated freestanding children's hospitals to report compliance with 3 Children's Asthma Care (CAC) core quality measures for accreditation and to improve asthma care.<sup>39,40</sup> The first 2 core measures assess compliance with evidence-based treatments for acute exacerbations, including the use of rescue inhalers and systemic corticosteroids. CAC-3 assesses compliance with preventive asthma measures to reduce readmissions, measured by the presence of a comprehensive home management plan of care, otherwise known as an AAP, at hospital discharge.<sup>40</sup> The CAC-3 measure has historically fallen short of benchmarks both nationally and locally, a gap that has been attributed to paper AAPs being difficult to relocate in the EHR when audited.<sup>39,41,42</sup> The eAAP has the potential to increase compliance with CAC-3 by being fully embedded in the EHR. Moreover, the connection of a patient's single AAP through the EHR to patient portals or through health information exchanges may further enhance patient engagement and continuity of care from the acute to the ambulatory settings.

#### Conclusions

This study supports existing evidence that patient self-management plays an important role in reducing asthma exacerbations. In addition, we show the feasibility of leveraging technology to provide guideline-based decision support through an eAAP, addressing known challenges of implementation into routine practice.

The authors gratefully acknowledge the Ambulatory Asthma Action Plan Committee for their commitment to and support of this project; the 5 pilot practices for testing the tool early on in development and providing crucial feedback; our acute care physician champions Dr. Matthew Sullivan and Dr. Cheryl Courtlandt; Dr. Jewell Carr and Dr. Thomas Ludden for their assistance in manuscript preparation; and Dr. Beau Mack, a former family medicine resident, who helped develop the webbased prototype.

#### References

 Centers for Disease Control and Prevention. Current asthma prevalence percents by age, United States: National Health Interview Survey, 2012. Available from: http://www.cdc.gov/asthma/nhis/ 2012/table4-1.htm. Accessed August 13, 2014.

- 2. Centers for Disease Control and Prevention. Current asthma population estimates, in thousands by age, United States: National Health Interview Survey, 2012. Available from: http://www.cdc.gov/asthma/nhis/2012/table3-1.htm. Accessed August 13, 2014.
- 3. Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. NCHS Data Brief 2012;(94):1–8.
- 4. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Full report 2007. Available from: http://www.nhlbi.nih.gov/guidelines/asthma/ asthgdln.pdf. Accessed April 10, 2014.
- 5. Yin HS, Gupta RS, Tomopoulos S, et al. Readability, suitability, and characteristics of asthma action plans: examination of factors that may impair understanding. Pediatrics 2013;131:e116–26.
- 6. Rank MA, Volcheck GW, Li JT, Patel AM, Lim KG. Formulating an effective and efficient written asthma action plan. Mayo Clin Proc 2008;83: 1263–70.
- Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004;59:94–9.
- Patel MR, Valerio MA, Sanders G, Thomas LJ, Clark NM. Asthma action plans and patient satisfaction among women with asthma. Chest 2012;142: 1143–9.
- Zemek RL, Bhogal SK, Ducharme FM. Systematic review of randomized controlled trials examining written action plans in children: what is the plan? Arch Pediatr Adolesc Med 2008;162:157–63.
- Gibson PG, Powell H, Coughlan J, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003;(1):CD001117.
- Ducharme FM, Zemek RL, Chalut D, et al. Written action plan in pediatric emergency room improves asthma prescribing, adherence, and control. Am J Respir Crit Care Med 2011;183:195–203.
- Hartert TV, Windom HH, Peebles RS Jr, Freidhoff LR, Togias A. Inadequate outpatient medical therapy for patients with asthma admitted to two urban hospitals. Am J Med 1996;100:386–94.
- Taylor DM, Auble TE, Calhoun WJ, Mosesso VN Jr. Current outpatient management of asthma shows poor compliance with International Consensus Guidelines. Chest 1999;116:1638–45.
- 14. Kaferle JE, Wimsatt LA. A team-based approach to providing asthma action plans. J Am Board Fam Med 2012;25:247–9.
- 15. Wisnivesky JP, Lorenzo J, Lyn-Cook R, et al. Barriers to adherence to asthma management guidelines among inner-city primary care providers. Ann Allergy Asthma Immunol 2008;101:264–70.

- Rastogi D, Shetty A, Neugebauer R, Harijith A. National Heart, Lung, and Blood Institute guidelines and asthma management practices among inner-city pediatric primary care providers. Chest 2006;129:619–23.
- Cabana MD, Rand CS, Becher OJ, Rubin HR. Reasons for pediatrician nonadherence to asthma guidelines. Arch Pediatr Adolesc Med 2001;155:1057–62.
- Gupta S, Wan FT, Hall SE, Straus SE. An asthma action plan created by physician, educator and patient online collaboration with usability and visual design optimization. Respiration 2012;84:406–15.
- Partridge MR. Written asthma action plans. Thorax 2004;59:87–8.
- Elward K, Blackburn B, Peterson LE, Greenawald M, Hagen MD. Improving quality of care and guideline adherence for asthma through a group self-assessment module. J Am Board Fam Med 2014;27:391–8.
- Carolinas HealthCare System. 2013 Value report: differentiable care and value within one integrated system. Available from: http://www.carolinashealthcare.org/ documents/chs/2013-value-report.pdf. Accessed March 16, 2015.
- 22. Rassen JA, Doherty M, Huang W, Schneeweiss S. Pharmacoepidemiology toolbox. Boston: Division of Pharmacoepidemiology & Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School. Available from: http://www.drugepi.org/dope-downloads/. Accessed September 26, 2013.
- Roberts NJ, Evans G, Blenkhorn P, Partridge MR. Development of an electronic pictorial asthma action plan and its use in primary care. Patient Educ Couns 2010;80:141–6.
- Hanson TK, Aleman M, Hart L, Yawn B. Increasing availability to and ascertaining value of asthma action plans in schools through use of technology and community collaboration. J School Health 2013;83:915–20.
- Murphy EV. Clinical decision support: effectiveness in improving quality processes and clinical outcomes and factors that may influence success. Yale J Biol Med 2014;87:187–97.
- Feldstein A, Elmer PJ, Smith DH, et al. Electronic medical record reminder improves osteoporosis management after a fracture: a randomized, controlled trial. J Am Geriatr Soc 2006;54:450–7.
- Heidenreich PA, Gholami P, Sahay A, Massie B, Goldstein MK. Clinical reminders attached to echocardiography reports of patients with reduced left ventricular ejection fraction increase use of betablockers: a randomized trial. Circulation. 2007;115: 2829–34.
- Bright TJ, Wong A, Dhurjati R, et al. Effect of clinical decision-support systems: a systematic review. Ann Intern Med 2012;157:29–43.
- 29. Gunathilake W, Gunawardena S, Fernando R, Thomson G, Fernando D. The impact of a decision

support tool linked to an electronic medical record on glycemic control in people with type 2 diabetes. J Diabetes Sci Technol 2013;7:653–9.

- Gill JM, Chen YX, Grimes A, Klinkman MS. Using electronic health record-based tools to screen for bipolar disorder in primary care patients with depression. J Am Board Fam Med 2012;25:283–90.
- Anderko L, Bartz C, Lundeen S. Wellness for a lifetime: improving lifestyle behaviors of low-income, ethnically diverse populations. Ann Fam Med 2005;3(Suppl 2):S35–6.
- 32. Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol 2012;129:1229–35.
- Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002–7. J Allergy Clin Immunol 2011;127:145–52.
- Zeiger RS, Hay JW, Contreras R, et al. Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol 2008;121:885–92.e5.
- Tapp H, Hebert L, Dulin M. Comparative effectiveness of asthma interventions within a practice based research network. BMC Health Serv Res 2011;11:188.
- 36. Tapp H, Kuhn L, Alkhazraji T, et al. Adapting community based participatory research (CBPR) methods to the implementation of an asthma shared decision making intervention in ambulatory practices. J Asthma 2014;51:380–90.
- Lavoie KL, Moullec G, Lemiere C, et al. Efficacy of brief motivational interviewing to improve adherence to inhaled corticosteroids among adult asthmatics: results from a randomized controlled pilot feasibility trial. Patient Prefer Adherence 2014;8:1555–69.
- Makela MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med 2013;107:1481–90.
- Zipkin R, Schrager SM, Keefer M, Marshall L, Wu S. Improving home management plan of care compliance rates through an electronic asthma action plan. J Asthma 2013;50:664–71.
- Nkoy FL, Fassl BA, Wolfe D, Colling D, Hales JW, Maloney CG. Sustaining compliance with pediatric asthma inpatient quality measures. AMIA Annu Symp Proc 2010;2010:547–51.
- 41. The Joint Commission. Improving America's hospitals: the Joint Commission's Annual Report on Quality and Safety. 2013. Available from: http:// www.jointcommission.org/improving\_americas\_ hospitals\_the\_joint\_commissions\_annual\_report\_ on\_quality\_and\_safety\_2013/. Accessed March 9, 2015.
- 42. Tolomeo C, Shiffman R, Bazzy-Asaad A. Electronic medical records in a sub-specialty practice: one asthma center's experience. J Asthma 2008;45:849–51.